TrialCancer chemotherapy and pharmacology2021

Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial.

Nora Isberner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.